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a b s t r a c t
The evolutionarily conserved DNA topoisomerase II beta-binding protein 1 (TopBP1) functions in DNA
replication, DNA damage response, and cell survival. We analyzed the role of TopBP1 in human and
bovine papillomavirus genome replication. Consistent with prior reports, TopBP1 co-localized in discrete
nuclear foci and was in complex with papillomavirus E2 protein. Similar to E2, TopBP1 is recruited to the
region of the viral origin of replication during G1/S and early S phase. TopBP1 knockdown increased,
while over-expression decreased transient virus replication, without affecting cell cycle. Similarly, using
cell lines harboring HPV-16 or HPV-31 genome, TopBP1 knockdown increased while over-expression
reduced viral copy number relative to genomic DNA. We propose a model in which TopBP1 serves dual
roles in viral replication: it is essential for initiation of replication yet it restricts viral copy number.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Papillomaviruses are approximately 8 kb double stranded DNA
viruses that infect basal cells of stratiﬁed epithelia and produc-
tively amplify in differentiated suprabasal cells (Bedell et al., 1991;
Howley, 1996). Human papillomavirus (HPV) genomes replicate as
low copy number autonomous episomes. Similarly, bovine papil-
lomavirus 1 (BPV-1) transforms murine cells and is maintained as
a stable multicopy nuclear plasmid (Law et al., 1981). Virally
encoded E1 and E2 proteins are essential for its replication during
S phase (Chiang et al., 1992; Mohr et al., 1990; Ustav and Stenlund,
1991), which depends on multiple host proteins such as DNA
polymerase δ, Replication Protein A and Brd4 (Park et al., 1994;
Wang et al., 2013). The E1 protein is a sequence speciﬁc DNA
binding helicase (Hughes and Romanos, 1993; Yang et al., 1993).
The E2 protein binds to speciﬁc DNA motifs in the viral regulatory
region and is a transcriptional activator (Androphy et al., 1987;
Phelps and Howley, 1987). E2 binds to E1; the transcriptional
activity of E2 is not essential for viral replication (Grossel et al.,
1996; Mohr et al., 1990). While metazoan origins typically span
50–250 kb, viral origins are deﬁned by short sequences of less than
100 bp. The E2–E1 complex recognizes their respective adjacent
motifs and this element acts as an origin of viral replication (ori).
The subsequent ATP hydrolysis by E1 causes the E2 protein to
dissociate and permits formation of hexameric E1 molecules on
the ori (Abbate et al., 2004; Sanders and Stenlund, 1998).
Topoisomerase II-binding protein 1 (TopBP1), also known as
Dpb11, Rad4, Cut5 (Yeast), Mus101 (Drosophila), is a functionally
conserved protein with a BRCA1-C terminus (BRCT) domain
[reviewed in Garcia et al. (2005)]. Vertebrate TopBP1 participates
in DNA replication and DNA damage repair processes (Balestrini et
al., 2010; Kumagai et al., 2010; Makiniemi et al., 2001), is essential
for cell survival (Yamane et al., 2002), and is required for
embryonic development (Jeon et al., 2011). TopBP1 is also neces-
sary for maintenance of genomic integrity (Kim et al., 2005) and
has several roles in the G1/S transition such as loading of replica-
tion components and activation of CycE/Cdk2 (Jeon et al., 2007).
Elevated expression of TopBP1 is believed to cause aggressive
tumors by modulating the p53 pathway (Liu et al., 2009). TopBP1
is capable of activating the DNA damage response pathway (DDR)
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2015.01.011
0042-6822/& 2015 Elsevier Inc. All rights reserved.
n Correspondence to: Department of Dermatology, Indiana University School of
Medicine, 980 W Walnut Street, C642, Walther Hall, Indianapolis, IN 46202, USA.
E-mail addresses: skangina@iu.edu (S. Kanginakudru),
mdesmet@iupui.edu (M. DeSmet), ysthomas@umail.iu.edu (Y. Thomas),
immorgan@vcu.edu (I.M. Morgan), eandro@iu.edu (E.J. Androphy).
Virology 478 (2015) 129–136
protein ATR (Kumagai et al., 2006) and is known to interact with
Claspin to promote Chk1 activity (Liu et al., 2006).
The HPV-16 E2 protein is known to associate with TopBP1 and
this interaction increases the transcriptional and replication activ-
ity of E2 protein (Boner et al., 2002). TopBP1 is believed to act as a
chromatin receptor of E2 protein especially in late stages of mitosis
(Donaldson et al., 2007). An HPV-31 genome with an E2 mutation
crippled for TopBP1 binding exhibited reduced replicative ability
(Donaldson et al., 2012). In U2OS cells transfected with HPV-18
genome, TopBP1 co-localized with E1 containing foci suggesting
association of TopBP1 with viral replication centers (Reinson et al.,
2013). These results imply co-operation between HPV proteins and
TopBP1 in facilitating viral replication. Although the DDR is
activated by HPV E1 and E7 proteins (Banerjee et al., 2011;
Fradet-Turcotte et al., 2011; Sakakibara et al., 2011), chemical
inhibitors of the DDR pathway did not alter HPV replication
(King et al., 2010; Reinson et al., 2013). In this context we explored
the role of TopBP1 in HPV and BPV replication by modulating the
levels of TopBP1 in different cell types.
Results
TopBP1 co-localizes with BPV E2 in nuclear foci
As it was previously reported that TopBP1 co-immunoprecipitates
with E2, we sought to further characterize this interaction in vivo. To
conﬁrm the protein–protein interaction between TopBP1 and E2, in-
situ proximity ligation assays (PLAs) were performed (Leuchowius et
al., 2011). PLA is a modiﬁed immunoﬂuorescence assay in which
secondary antibody is conjugated to speciﬁc DNA sequences. When
two secondary antibodies are in close proximity (40 nm), DNA can
be ligated, ampliﬁed and detected by hybridization with speciﬁc
ﬂuorescent probes. In BPV-A3 cells, we detected the in vivo interac-
tion between the E2 protein and endogenous TopBP1 as
demonstrated by formation of ﬂuorescent spots inside the nucleus.
We also observed similar interaction between E1 and E2 (Fig. 1A).
These cells harbor hundreds of copies of BPV genome due to high
levels of an E2 protein with three serine to alanine mutations
(McBride and Howley, 1991). We also repeated the assay in C127
cells transfected with (or without) BPV-E2. C127 cells transfected
with BPV-E2 became positive in PLA reactions with TopBP1 (Fig. 1B).
Transfection efﬁciency was normalized to GFP expression and PLA
signals were counted in transfected cells. As shown in the graph, not
all C127 cells showed the PLA signal, possibly because of low level or
a transient interaction between E2 and TopBP1. More than 30% of the
cells with PLA signal had more than one such ﬂuorescent puncta.
TopBP1 is localized near the BPV and HPV ori in G1/S and early S
phase
We next investigated whether TopBP1 is recruited to the viral
genome. BPV-A3 cells harboring replicating BPV genomes were
synchronized in different stages of cell cycle using mimosine,
double thymidine or nocodazole. Cell cycle proﬁles were analyzed
by ﬂow cytometry. As shown in the inset of Fig. 2A, cells
accumulated in G1/S, early S and G2 after mimosine, double
thymidine and nocodazole treatment respectively. Since papillo-
mavirus oncoproteins are known to abrogate cell-cycle check-
points (Heilman et al., 2009; Liu et al., 2007), we observed that
BPV-A3 cells were not completely arrested and a small portion of
cells progressed through cell cycle. ChIP was performed using BPV
E2, TopBP1 or control EE antibodies. As expected (Melanson and
Androphy, 2009), BPV E2 was present at the LCR region at very
high levels in mimosine and double thymidine synchronized cells.
Compared to the EE antibody control, TopBP1 ChIP was increased
by 40 fold in mimosine treated G1/S cells and by 12 fold in double
thymidine treated early S phase cells. Levels slightly above back-
ground (EE antibody) were detected in nocodazole treated mitotic
arrested cells (Fig. 2A). These results conﬁrm enrichment of
Fig. 1. In vivo co-localization of BPV-E2 with TopBP1. (A) In-situ proximity ligation assay (PLA) between E1–E2 (left) and TopBP1–E2 (right) in BPV-A3 cells synchronized by
double-thymidine block. Fluorescent spots indicate interaction based PCR ampliﬁcation occurring in the nucleus (stained blue). (B) PLA of transfected BPV E2 and
endogenous TopBP1 in C127 cells synchronized by double thymidine. Fluorescent spot indicates interaction based PCR ampliﬁcation. Graph shows the percentage
distribution of PLA signals in GFP expressing transfected C127 cells.
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TopBP1 near the viral origin in G1/S or early S phases. TopBP1 is
similarly localized to the LCR region in HPV-BP cells harboring
episomal HPV-16 genome (Fig. 2B) in a cell cycle dependent
manner. The fold change in HPV-BP was not as high as that of
BPV, likely due to antibody afﬁnity and/or copy number difference.
Our results also reafﬁrm that the virus replication is in synchrony
with cell cycle and initiated in S phase during episomal main-
tenance. We could not detect the endogenous HPV-16 E2 protein
in HPV-BP cells due to lack of a speciﬁc antibody.
Over-expression of TopBP1 inhibits while its depletion promotes viral
replication
We sought to understand the role TopBP1 might play in viral
replication. We used two human cell lines to examine the effect of
TopBP1 in transient replication assays: H1299, a non-small cell
lung carcinoma cell line that has been successfully used for stable
knockdown of TopBP1 (Liu et al., 2011) as well as for under-
standing HPV E6 and E7 functions (Mesplede et al., 2012;
Todorovic et al., 2012) and C33A, a cervical carcinoma cell line
often used in HPV replication assays. HPV-31 E1, E2 and the
pFLORI31 reporter plasmids were co-transfected with either
TopBP1 over-expression or knockdown constructs. There was
signiﬁcant reduction in protein level with the pSUPER-siTopBP1
construct compared to pSUPER-siScramble while over expression
resulted in two to three fold increased TopBP1 (Fig. 3A). At 48 h,
knockdown of TopBP1 in both H1299 and C33A increased viral
replication by 48% and 26% respectively. In contrast, its over-
expression resulted in a nearly two fold decrease in HPV-31
replication in H1299 and 21% reduction in C33A cells. At 72 h
post-transfection, the effects were more pronounced with knock-
down causing 60% and 40% increase in viral replication in H1299
and C33A respectively, while over-expression decreased the viral
replication by 60% and 46% in H1299 and C33A respectively
(Fig. 3B). As shown in Fig. 4A and B, modulation of TopBP1 protein
levels did not signiﬁcantly affect cell cycle compared to respective
controls. We did observe that the pSUPER vector backbone slightly
altered the “S” phase (as shown by pSUPER-siSCramble) in C33A
cells, but the cell cycle patterns were similar for both pSUPER-
siTopBP1 and pSUPERsi-Scrambled samples. Using trypan blue
staining, we did not detect any signiﬁcant cell death associated
with TopBP1 manipulations in C33A or H1299, as treatments
showed similar (9474%) cell survival.
Although we normalized the ﬁreﬂy luciferase (replication
related) activity to renilla luciferase (transcription related) activity,
Fig. 3. Transient HPV-31 replication was altered by modulating TopBP1 levels.
(A) Western blot of TopBP1 in H1299 and C33A cells. Left panels show the western
blot from H1299 and C33A cells transfected with pSUPER-siTopBP1 or its vector
control. Right panel shows the western blot from H1299 cells transfected with
vector or Flag-TopBP1 constructs. Actin was used as a loading control. Legend – V –
vector controls, sh – pSUPER-siTopBP1, FT – Flag-TopBP1. (B) HPV-31 luciferase
based assays in H1299 (upper) and C33A (lower) cells having either knockdown or
over-expression constructs of TopBP1. po0.05 between control and over-expres-
sion/knockdown at both time points for H1299, while it was signiﬁcant at 72 h
for C33A.
Fig. 2. Both E2 and TopBP1 ChIP to the LCR region at G1/S and early S stages.
(A) BPV-A3 cells were treated with mimosine, double thymidine or nocodazole to
arrest in different cell cycle stages. Inset diagram shows ﬂow cytometry based cell
cycle analysis. Bar indicates standard deviation, *po0.05 between TopBP1 antibody
and control antibody. (B) TopBP1 is localized to HPV-16 LCR of HPV-BP cell line. Bar
indicates standard deviation, *po0.05 between TopBP1 antibody and control
antibody.
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we wished to conﬁrm that the observed result was a result of
genome replication. We repeated this assay by excluding HPV-31-
E1 or E2. As shown in Fig. 5, the absence of E1 or E2 resulted in
nearly 20 fold decrease in luciferase activity. In the absence of viral
proteins, there was no signiﬁcant difference in luciferase activity,
suggesting an inﬂuential role of TopBP1 on E1–E2 dependent
replication.
To demonstrate the consequences of TopBP1 manipulation
on a stable HPV replicon, HPV-BP cells were transfected with
either over-expression or shRNA constructs of TopBP1. After 48
or 72 h post-transfection, total DNA was isolated and viral copy
number was determined by real time PCR using primers speciﬁc
for the HPV-16 LCR region. A genomic DNA amplicon was
included for normalization. Viral copy number increased to
Fig. 4. TopBP1 level does not alter cell cycle. C33A (A) and H1299 (B) cells were transfected with either over-expression or knockdown constructs (or respective controls).
Flow analysis was carried out 48 h post-transfection.
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150% at 48 h post-transfection and nearly three fold in TopBP1
knockdown cells at 72 h (Fig. 6A and B). On the other-hand,
over-expression of TopBP1 resulted in 20% and 50% reduction in
copy number at 48 and 72 h respectively. We also tested
whether analogous observations would hold in CIN612 cells.
As shown in Fig. 6B, heterologous expression of TopBP1 sig-
niﬁcantly decreased viral copy number relative to genomic DNA
while knockdown increased viral content. Therefore, TopBP1 not
only effects viral replication in transient assays, but also reduces
viral copy number in cells maintaining HPV episomes.
Discussion
Papillomavirus genomes are maintained as low copy number
episomes in basal epithelial cells and are ampliﬁed to thousands of
copies in nuclei of upper level differentiating cells. While activa-
tion of the DDR pathway is known to stimulate the ampliﬁcation
stage, a role for DDR factors in the genome maintenance phase has
not been observed. In the present study, we investigated the role
of TopBP1 protein in HPV and BPV replication. TopBP1 plays an
essential role during genomic DNA replication by facilitating
loading of CDC45 at the origin (Kumagai et al., 2010). After
replication initiates, TopBP1 is no longer necessary for continued
DNA synthesis (Makiniemi et al., 2001). We demonstrate that the
TopBP1 protein is present at the HPV and BPV origins of replication
in G1/S phases of cell cycle (Fig. 2A and B). This is presumably
facilitated by its binding to the HPV E2 protein in vivo as shown
here by in-situ PLA. We also observed interaction between BPV E1
and E2 by PLA in a murine cell line that stably maintains viral
episomes (Fig. 1A). In addition to strong signals, E1–E2 PLA
showed a few faint signals, which were not observed in E2–
TopBP1 interactions, possibly because of different afﬁnities of
proteins to each other and/or to the speciﬁc antibodies. The cell
cycle speciﬁc localization of TopBP1 to the viral origin in G1/S
implicates its role in the initiation of viral DNA replication. This is
supported by a previous study wherein an HPV-16 genome
encoding an E2 mutant crippled for TopBP1 failed to be main-
tained episomally in cultured keratinocytes (Donaldson et al.,
2012). As the cells progressed through mitosis, the presence of
TopBP1 near the viral ori decreased, indicating its displacement at
this stage (Fig. 2A and B). It has been reported that the E2 binding
protein Brd4 is also necessary for initiation of HPV replication and
subsequently displaced from viral DNA foci (Sakakibara et al.,
2013; Wang et al., 2013). Our results suggest a similar role for
TopBP1.
Progression of a replication fork may stall upon collision with
other DNA bound complexes, or when the template is damaged as
occurs with nucleotide depletion or from chemical agents. Induc-
tion of DNA damage following HPV-18 E1 over-expression has
been shown by comet assay (Reinson et al., 2013). This implies that
E1 or an associated factor is capable of inducing genomic damage
and the DDR. TopBP1 is recruited to the replisome by DDR
mediators of the Mre11–Nbs1–Rad50 complex (Duursma et al.,
2013; Makiniemi et al., 2001). Phosphorylated TopBP1 is necessary
for a cascade of downstream protein phosphorylations that result
in activation of Chk1, which restricts further origin ﬁring (Feijoo
et al., 2001). We observed that partial knockdown of TopBP1
consistently increased transient viral replication and viral epi-
somes (Figs. 3 and 6). The opposite outcome was observed
following over-expression of TopBP1, which resulted in reduced
viral replication in luciferase based reporter assays. We conﬁrmed
that the change in replication is a consequence of TopBP1 level on
replication unrelated to cell cycle (Fig. 4A and B). Moreover,
heterologous expression of TopBP1 consistently decreased viral
copy number in keratinocytes stably carrying episomal HPV-16 or
HPV-31 genomes (Fig. 6). In the absence of E1 or E2, replication
was not observed irrespective of TopBP1 protein level (Fig. 5). We
conclude that the sustained presence of TopBP1 hindered virus
replication.
Targeting the TopBP1 pathway is not unprecedented in viral
replication. Certain adenovirus serotypes inhibit ATR activation by
targeting the TopBP1 protein for degradation, inferring that the
DDR restricts adenoviral replication (Blackford et al., 2010).
Another indirect link between TopBP1 and HPV replication may
lie in the Fanconi Anemia (FA) pathway. FA is associated with
increased susceptibility to HPV induced carcinogenesis (Kutler
et al., 2003; Park et al., 2010). The viral E7 oncoprotein was
Fig. 5. TopBP1 effect on HPV-31 replication depends on both E1 and E2. HPV-31
luciferase based assays in C33A cells with or without HPV-31 E1/E2 in TopBP1
knockdown or over-expressing cells. *po0.05.
Fig. 6. Episomal HPV replication is altered by changing TopBP1 levels.
(A) Quantitative PCR of HPV-16 LCR in TopBP1 protein knockdown or over-
expressing HPV-BP cells. HPV-16 LCR DNA values were normalized to PCR of
genomic locus 23. *po0.05. (B) Quantitative PCR of HPV-31 LCR in TopBP1 protein
knockdown or over-expressing CIN612 cells. HPV-31 LCR values were normalized
to PCR of genomic locus 23. *po0.05.
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reported to activate the FA pathway and accelerated chromosomal
instability has been attributed to a defective FA pathway (Spardy
et al., 2007). The FA pathway is believed to restrict the HPV life
cycle as loss of FANCD2 component accelerates HPV ampliﬁcation
(Hoskins et al., 2012). Defective FANCM is also known to displace
TopBP1 from chromatin (Schwab et al., 2010). Whether there is
any link between HPV ampliﬁcation and failure to retain TopBP1
on chromatin in FA is not very clear, but our results do indicate
that after replication is initiated, removal of TopBP1 would facil-
itate HPV replication during episomal maintenance.
The experiments presented here suggest differential roles of
TopBP1 in PV replication. Chromatin immunoprecipitation (ChIP)
results support the essential role of TopBP1 for replication initia-
tion, while over-expression of TopBP1 exerts a negative regulatory
role. We believe that, as a key regulator of the DDR pathway,
TopBP1 plays a critical role in fork stability during episomal
replication. Since PV replication is presumed to occur by bidirec-
tional DNA synthesis, the replication fork will converge on each
episome. This poses the problem of colliding replisomes that
require resolution. The DDR may be critical to appropriately
resolve this possible fork collapse. A collapsed fork is likely to
affect episomes more severely than the genomic DNA since the
latter have multiple origins and thus could restart more efﬁciently.
Alternatively, manipulation of the DDR by modulating the levels of
TopBP1 may cause a replication block from which the episomal
DNA cannot be rescued. A previous study using chemicals to alter
HPV DNA structure showed that mounting of a DDR eliminated
HPV episomes, possibly by activating Rad9–Hus1–Rad1 (9–1–1)
(Edwards et al., 2013). It was suggested that the 9–1–1 complex
recruits enzymatic complexes that destroyed the HPV genomes.
Our study also suggests that unscheduled or uncontrolled activa-
tion of TopBP1 is not conducive for PV replication, reconﬁrming
the ﬁne balance of host proteins for successful replication and
episome maintenance. We also cannot rule out the possibility of
TopBP1 playing a role during DNA segregation that affects episo-
mal copy number. In differentiating cells where HPV undergoes
rapid ampliﬁcation, the DDR is a critical factor for promoting virus
replication and the potential role of TopBP1 might be altogether
different. Further studies are necessary to uncover the exact
mechanism by which TopBP1 leads to episomal loss and/or
replication block during HPV maintenance and how and when
exactly TopBP1 is displaced during replication.
Materials and methods
Cell culture, plasmids, chemicals
C127, BPV-A3 murine C127 cells with BPV-1 episomes
(Voitenleitner and Botchan, 2002), C33A, and J2 3T3 cells were
maintained in DMEM with 10% FBS and 1 Pen/Strep. H1299 cells
were maintained in RPMI media with 10% FBS having 1 Pen/
Strep. HPV-BP cells (Sprague et al., 2002) that maintain 10–50
copies of HPV-16 episomes were cultured in Keratinocyte Serum
Free media (K-SFM) supplemented with bovine pituitary extract,
EGF (Invitrogen) and 1 Pen/Strep. CIN612-9E cells (De Geest et
al., 1993) that retain HPV-31 episomes were grown in E-Media on
J2 3T3 feeders pre-treated with 5 mg/ml mitomycin C as described
(Bedell et al., 1991). Cells were transfected with Lipofectamine
2000 (C33A, H1299, BPV-A3) or with FugeneHD (HPV-BP, CIN612)
at 1:1 and at 4:1 ratio to DNA, respectively. We obtained plasmids
HPV-31 E1, E2, pFLORI31 and pCI-Rluc (Fradet-Turcotte et al.,
2010a), pSUPER-siScramble (knockdown control), pSUPER-
siTopBP1 and full length human Flag-TopBP1 (Liu et al., 2004).
The TopBP1 knockdown constructs used are human speciﬁc. pCG-
BPV-E2 has been reported (Grossel et al., 1996). We used empty
pcDNA3 as vector control. Mimosine and nocodazole were pro-
cured from Sigma, and thymidine was obtained from Alfa Aesar
(Ward Hill, MA).
Antibodies
BPV anti-E2 (B201, II–I), anti-EE antibodies (Wang et al., 2009),
and rabbit anti-TopBP1 (Donaldson et al., 2007) have been
reported. Commercial antibodies used were anti-Actin, (Sigma-
Aldrich) and mouse anti-TopBP1 (BD Transduction Laboratories,
611875).
Luciferase assay for viral replication
Luciferase based replication protocols essentially followed as
described (Fradet-Turcotte et al., 2010b). Brieﬂy, 80 ng each of
HPV-31 E1, E2 and pFLORI31 constructs were co-transfected along
with 1 mg of TopBP1 shRNA (pSuper-siTopBP1) or over-expression
(Flag-TopBP1) vectors or their respective controls (pSUPER-siS-
Cramble, or pCDNA3) in 12 well plate. For normalization, pCI-RLuc
construct was included at 16 ng per well. Cells were lysed in Dual-
Glo luciferase reagent (Promega) and both ﬁreﬂy and renilla
luciferase activities were determined using PHERAStar FS (BMG
Labtech). Luciferase activities were measured 48 h and 72 h after
transfection. Relative replication was expressed by the ratio of
ﬁreﬂy to renilla luciferase activity normalized to vector control.
Viral genome copy number determination by real time PCR
Cells were transfected with 2 mg of TopBP1 over-expression or
knockdown constructs or their respective controls. 72 h post-transfec-
tion, HPV-BP or CIN612 cells were lysed in 10 mM Tris–1mM EDTA
(pH 8.0) with 0.1% SDS and 1 protease inhibitor cocktail, DNA was
isolated using a standard phenol:chloroform (PCA) method (Sambrook
and Russell, 2006). Real time PCR was performed with a BioRad CFX
using Sso Fast Evagreen mastermix (BioRad) according to manufac-
turer's protocol. The PCR primer sets were HPV-16 LCR: forward 50
GGGTGTGTGCAAACCGTTTTGGGTTA 30 and reverse 50 CCGATTTCGGT-
TACGCCCTTAGTTT 30; HPV-31 LCR: forward 50 CCTGCTCCTCCCAA-
TAGTCAT 30 and reverse 50 AAACGGACCGGGTGTACA 30. DNA primer
set #23 (Mendoza-Maldonado et al., 2010) was used for genomic DNA
copy number determination. Results were analyzed using CFX man-
ager software (BioRad).
Chromatin immunoprecipitation (ChIP) assay
BPV-A3 or HPV-BP cells were synchronized as follows. For
double thymidine block, cells were kept in 2.0 mM thymidine
overnight, released in the morning and again blocked overnight
with 2.0 mM thymidine. For the mimosine block, cells were
treated at 2 μM overnight. For G2 arrest, cells were treated at
100 nM of nocodazole overnight. After treatment, ChIP was per-
formed as described in Yu et al. (2007). Primer sets used for BPV–
LCR were forward 50 GCCTTCTCAGCCAAAATGAA 30 and reverse
50 TGAGGTTTTGATCCGCCTAC 30
Flow cytometry
Synchronized cells were ﬁxed in 90% ethanol and stored in 4 1C.
The following day, cells were washed in PBS, treated with 50 μg/
ml of RNase A–50 μg/ml Propidium iodide for 20 min, run on FACS
Caliber and analyzed with FlowJo software. To test the effect of
TopBP1 protein levels on cell cycle, C33A or H1299 cells were
transfected with either over-expression or knockdown plasmids.
After 48 h, cells were harvested and processed for ﬂow cytometry.
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Western blot of TopBP1
H1299 or C33A cells were transfected with pSUPER-siTopBP1 or
pSUPER-siScramble at 3 μg per well of a six well plate. After 48 h,
cells were lysed in urea buffer (6 M urea, 100 mM NaH2PO4, and
20 mM Tris pH-6.8). 20 mg of total protein was run on a 4–15%
gradient gel (BioRad) and transferred onto PVDF membranes.
Rabbit anti-TopBP1 (R1180) antibody was used at 1:2000, and
anti-Actin antibody at 1:1000 dilutions. For over-expression stu-
dies, H1299 cells were transfected with vector control or Flag-
TopBP1 plasmids at 3 μg per well of a six well plate.
In-situ proximity ligation assay (PLA)
In-situ PLA was performed using the PLA Red kit (Olink
Biosciences). BPV-A3 cells were ﬁrst blocked in S phase by double
thymidine treatment, ﬁxed in 4% para-formaldehyde for 10 min,
permeabilized for 15 min in 0.5% Triton-X 100/PBS, washed in PBS,
blocked with 5% goat serum in 0.2% Triton-X 100/PBS, then
incubated overnight with primary antibody combinations (E2–
TopBP1 or E1–E2) at 4 1C. The PLA then followed the manufac-
turer's protocol. Brieﬂy, cover slips were washed in buffer A,
incubated with PLA probe PLUS and MINUS for one hour at
37 1C, washed twice and the probes were ligated for 30 min.
Ampliﬁcation was performed for 100 min at 37 1C, washed twice
in buffer A and B. Cover slips were mounted in Duolink in-situ
mounting media. Cells were analyzed with a Nikon microscope. In
case of C127 cells, eGFP was co-transfected with or without pCG-
E2. PLA signals were counted only from green ﬂuorescent cells.
Two independent transfections were carried out, the counts were
averaged and calculated as percentage of transfected cells display-
ing PLA foci.
Statistical analysis
Unless speciﬁcally mentioned, all experiments were repeated thrice
and results were averaged. Error bars denote the standard deviation.
Statistical signiﬁcance was determined using Student's t-test.
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